Francesca Conradie Dr. Francesca Conradie leads a clinical unit dedicated to improving the diagnosis and treatment outcomes for both drug sensitive Tuberculosis (TB) and drug resistant TB through clinical research and translation of research findings in national and international policy. In line with the ambitious WHO goal of eradicating TB by 2030, Dr Francesca Conradie has also made this part of her mission.
Dr Francesca Conradie was the Principal Investigator for the TB Alliance trial NiX, which led to the registration by the FDA of BPaL. She is also the holder of the USAID Grant BEAT Tuberculosis investigation, a short all oral regimen for Rifampicin Resistant tuberculosis (RR-TB). She heads the operational research introducing BPaL into the South African NTP. She has been the co-chair of the National Clinical Advisory Committee since 2012 of the South African NTP. This body was formed originally to provide clinical governance to TB clinicians and to provide expert clinical advice to the National Drug-Resistant TB directorate. This committee has provided input into the National RR-TB guidelines and has advised on the addition of new drugs into the treatment guidelines.